Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Best GLP-1 With Active Savings Card 2026: Which $25 Offer Actually Works for You?
By The RX Index Editorial Team · Last verified:
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
The best GLP-1 with an active savings card in 2026 depends on your insurance, not the drug name — and that’s the part the ads leave out. If you have commercial insurance (the kind you get through a job or buy yourself) and it covers your medication, Foundayo, Zepbound, and Wegovy all run active cards that drop the cost to as little as $25 a month. If your plan doesn’t cover the drug, the picture flips: Foundayo’s brand-name self-pay price starts at $149/month, Zepbound vials at $299/month, and Wegovy’s pen at roughly $199–$499 depending on dose.
So yes — the $25 is real. It’s just not real for everyone. Below, we line up every active card side by side, show you which group you fall into, and explain what to do when the pharmacy rings up way more than $25 (it happens a lot, and there’s usually a fix).
Last verified: · Sources: Novo Nordisk, Eli Lilly, NovoCare, LillyDirect, CMS, and the manufacturers’ current pricing pages (full list at the bottom)
Disclosure: We may earn a commission if you start care through some links here, at no extra cost to you. The manufacturer savings cards on this page are free and come straight from the drugmaker — we earn nothing on those.
The 2026 active GLP-1 savings card matrix
This is the table you’d otherwise build yourself by opening a half-dozen drugmaker pages. We did that for you. It scrolls sideways on a phone.
Active 2026 GLP-1 savings cards — what you actually pay, by insurance situation (verified ; drugmaker terms can change)
| Medication (form) | Approved for | If commercial insurance covers it | If not covered / self-pay | Cap & expires | The catch |
|---|---|---|---|---|---|
| Foundayo (orforglipron — pill) | Weight loss | As little as $25/mo | $149/mo (0.8 mg), $199 (2.5 mg), up to $299 at higher doses | $100/mo, $1,000/yr; expires 12/31/2026 | Brand-new (April 2026); coverage is still spreading |
| Zepbound (tirzepatide — injection) | Weight loss; sleep apnea | As little as $25/mo | Single-dose pen $499; vials/KwikPen $299 / $399 / $449 by dose | $100/mo, $1,300/yr; expires 12/31/2026 | The vial price needs a refill within 45 days to hold |
| Wegovy (semaglutide — pen or pill) | Weight loss; heart-risk reduction | As little as $25/mo | Pen self-pay ~$199–$499 by dose/offer; pill from $149 | $100/mo (down from $225 in 2025) | A high copay can leave you above $25 even with the card |
| Ozempic (semaglutide — injection) | Type 2 diabetes | As little as $25/mo for up to 3 months | Injection $199 (first 2 fills) then $349–$499; tablets $149 / $199 / $299 | $100/mo, $1,001/yr | It’s a diabetes drug, not a weight-loss brand |
| Mounjaro (tirzepatide — injection) | Type 2 diabetes | As little as $25 for up to a 3-month fill | $499/mo if not covered | $150/mo, $1,950/yr; expires 12/31/2026 | The card needs a diabetes prescription |
| Rybelsus (oral semaglutide — pill) | Type 2 diabetes | As little as $25/mo | No broad brand-name self-pay card on the same terms | $100/mo | Diabetes use, not a weight-loss shortcut |
| Trulicity (dulaglutide — injection) | Type 2 diabetes | As little as $25 for up to a 3-month fill | Limited self-pay help | $150/mo, $1,950/yr; expires 12/31/2026 | Older diabetes option; not a 2026 weight-loss pick |
Note: Saxenda (liraglutide) is sometimes listed as a GLP-1 weight-loss option, but its manufacturer savings offer was discontinued for new patients in 2023, so it is not an active 2026 savings-card choice.
Three rules sit under every card above. Read them once and the whole table makes sense:
- You need commercial insurance. A savings card is a coupon that rides behind your private plan. Medicare, Medicaid, VA, and TRICARE are excluded from these commercial cards by federal law. Separate self-pay and direct-purchase options exist (more below), but those generally can’t be counted toward your deductible or out-of-pocket max.
- Your plan has to already cover the drug. The card lowers your copay — it doesn’t create coverage. (Lilly does offer separate “not-covered” self-pay cards for people whose commercial plan excludes the drug.)
- “$25” is the floor, not a promise. You save up to a cap. The weight-loss brands (Foundayo, Zepbound, Wegovy) cap at $100/month; the diabetes brands (Mounjaro, Trulicity) cap at $150/month. If your copay is at or under the cap, you land near $25. If it’s higher, you pay the difference.
Best for: anyone with commercial insurance who wants a straight answer on coverage before picking a drug.
Which GLP-1 has the best active savings card in 2026?
For weight loss, the strongest active savings cards in 2026 belong to Foundayo, Zepbound, and Wegovy — each advertises as little as $25 a month with commercial insurance that covers the drug. The right “best” pick changes based on whether your plan covers it, whether you want a pill or a shot, and whether you qualify for the card at all.
Here’s the fast version, by where you stand:
| Your situation | Best first move | Why |
|---|---|---|
| Commercial plan covers a weight-loss GLP-1 | Foundayo, Zepbound, or Wegovy | All three can reach ~$25 when you’re eligible |
| Commercial plan doesn’t cover it | Foundayo first | Lowest verified brand-name self-pay floor: $149/mo |
| You need help getting approved | Ro (sponsored affiliate link, opens in a new tab) | Free coverage check, plus help with the prior-authorization paperwork |
| You’re paying cash and want choices | Sesame (sponsored affiliate link, opens in a new tab) | Publishes self-pay branded prices and lets you pick a provider |
| You’re on Medicare | The Medicare GLP-1 Bridge | $50/mo starting July 1, 2026 (details below) |
Best for: confirming the $25 path is realistic for your specific plan.
Who actually qualifies for a $25 GLP-1 savings card — and who doesn’t?
You qualify for a GLP-1 savings card if you’re a U.S. resident with commercial or private insurance, and the card then lowers your copay on a drug your plan already covers. You don’t qualify for the commercial card if you have Medicare, Medicaid, VA, or TRICARE — federal anti-kickback rules block drugmaker copay cards for government plans. And the advertised “$25” is the lowest possible price, not the guaranteed one, because each card only pays up to a monthly cap.
Let’s make that cap real with a number, because this is exactly where people get surprised:
Copay: $120 · Card cap: $100
You pay ~$25 🎉
Copay: $250 · Card cap: $100
You pay $150 😨
Same card. Same drug. Totally different price — and the only thing that changed is your plan’s copay. One real example we keep seeing: people whose Wegovy cost jumped in 2026 because Novo Nordisk cut the monthly cap from $225 down to $100. Their card still “worked.” Their price still went up. That’s the cap doing its quiet thing.
Find your group in five seconds:
- Commercial insurance that covers your drug → use the card. This is the $25 lane.
- Commercial insurance that doesn’t cover your drug → the standard card won’t help much; use a manufacturer self-pay card instead (next section).
- Medicare / Medicaid / VA / TRICARE → the commercial card is off the table; jump to the Medicare section.
- No insurance at all → not in the $25 commercial-card lane, but manufacturer self-pay offers and assistance programs may still apply.
Best for: commercial-insurance members confirming eligibility before they choose.
How much does each GLP-1 savings card really save in 2026?
With commercial coverage, Foundayo, Zepbound, Wegovy, Ozempic, Mounjaro, and Rybelsus each bring eligible patients to about $25 a month. The real differences show up in the savings cap and — more importantly — in the self-pay price you fall back to if your plan doesn’t cover the drug. Here’s each one, punchline first.
Foundayo (the new oral option) — lowest self-pay floor
Foundayo (orforglipron) is Eli Lilly’s once-daily weight-loss pill, FDA-approved on April 1, 2026, and the only one you can take any time of day with no food or water rules. With commercial coverage, eligible patients pay as little as $25/month. If your plan doesn’t cover it, Lilly’s self-pay card runs $149/month for the 0.8 mg dose, $199 for 2.5 mg, and up to $299 at higher doses. The card caps savings at $100/month ($1,000/year) and expires December 31, 2026.
Zepbound — strongest injection savings path, biggest yearly cap
Zepbound (tirzepatide) is Lilly’s weight-loss and sleep-apnea injection. Covered commercial patients pay as little as $25 per fill, with the highest yearly ceiling of the group — up to $1,300 a year. Not covered? The single-dose pen runs $499/month, but Lilly’s self-pay vials and KwikPen are cheaper: $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg). One rule to respect: you have to refill within 45 days to keep that vial price. Card expires December 31, 2026.
Wegovy — the semaglutide standard, with a smaller cap this year
Wegovy (semaglutide) comes as a pen or a pill and is approved for weight loss and for lowering heart risk. Covered commercial patients pay as little as $25/month — but remember, Novo Nordisk dropped the monthly cap to $100 for 2026, so a bigger copay can leave you above $25. No coverage? Self-pay for the pen runs about $199–$499 depending on dose and current offer, and the Wegovy pill starts around $149.
Ozempic — a diabetes card, not a weight-loss workaround
Ozempic (semaglutide) is approved for type 2 diabetes, not weight loss, though clinicians sometimes prescribe it off-label. Covered commercial patients pay as little as $25 for a 1-to-3-month supply, capped at $100/month (up to $1,001/year). Self-pay through NovoCare is $199 for your first two fills, then $349–$499 for the injection; the tablets are listed at $149, $199, and $299 by dose. Insurance often denies Ozempic when it’s prescribed for weight loss rather than diabetes, so check coverage first.
Mounjaro & Rybelsus — diabetes brands, same $25 logic
Mounjaro (tirzepatide injection) and Rybelsus (oral semaglutide) are both type 2 diabetes medicines. Each offers as little as $25 with commercial coverage. Mounjaro’s card caps savings at $150/month ($1,950/year) and runs $499/month if your plan doesn’t cover it — but it specifically requires a diabetes prescription, since Mounjaro isn’t FDA-approved for weight loss. Don’t pick a diabetes drug for savings reasons; match the medicine to the diagnosis your clinician treats.
Best for: anyone deciding between two covered drugs who wants the real copay first.
What if your insurance doesn’t cover it — or you’re paying cash?
If your commercial plan doesn’t cover the GLP-1, your cheapest path usually shifts from “copay card” to “manufacturer self-pay offer.” Foundayo has the lowest verified brand-name self-pay floor at $149/month, the Wegovy pill also starts at $149, and Zepbound vials start at $299. You are not stuck with the $1,000+ list price — almost nobody actually pays that.
| Your situation | Best path | Roughly what you pay |
|---|---|---|
| No insurance | Manufacturer self-pay pharmacy | Foundayo from $149 · Zepbound vials from $299 · Wegovy/Ozempic by dose |
| No insurance, want to comparison-shop | TrumpRx.gov (federal price-comparison portal) | Lists lows like Wegovy pill $149, injectables from ~$199, Zepbound from $299 |
| Uninsured + lower income | Patient Assistance Program (PAP) | Possibly free, under income limits |
| On Medicare Part D | Plan coverage + the new Medicare GLP-1 Bridge | $0 after the yearly Part D cap; $50/mo via the Bridge (below) |
| On Medicaid | Your state’s Medicaid list | Varies a lot by state |
A quick word on “self-pay savings cards”: they’re real and worth using, but they’re a different animal from the $25 copay card. The $25 card needs covering insurance. The self-pay card is for people without coverage paying out of pocket directly to the drugmaker — same brand-name medicine, different door.
And about TrumpRx: TrumpRx.gov launched in February 2026 as a federal price-comparison site. It doesn’t sell drugs or write prescriptions — it shows cash prices and routes you to manufacturer or discount pathways (it runs on GoodRx’s pricing technology). Because it’s a cash-pay route, anything you spend there generally won’t count toward your insurance deductible or out-of-pocket max. If your plan covers a GLP-1, your copay card may still beat it.
Can patient assistance beat a savings card?
For uninsured people who qualify by income, a Patient Assistance Program (PAP) can beat any card — because it can make the medicine free. Novo Nordisk’s PAP can provide Wegovy or Ozempic at no cost to uninsured patients under its income limits, and Lilly Cares can provide prescribed Lilly medicines free for up to 12 months to qualifying patients. The trade-off is paperwork and proof of income, and you generally have to be uninsured (not just under-covered). If that’s you, it’s worth the effort before you pay anything.
Best for: people whose plan won’t cover it, or who’d rather skip the insurance fight entirely.
Why didn’t the savings card give me the $25 price?
A savings card can be fully active and still fail to give you $25 at the counter. The most common reasons are that your plan doesn’t cover the drug, your copay is bigger than the card’s cap, the pharmacy processed the card incorrectly, you’ve hit a monthly or yearly limit, or you’re on a government plan. The good news: most of these have a fix.
1. Your plan doesn’t cover the drug.
“Commercial insurance” isn’t enough on its own — the plan has to cover that exact medicine.
Fix: Check coverage first, and if it’s denied, ask about a prior authorization (your doctor’s request asking the insurer to approve it).
2. Your copay is bigger than the card’s cap.
Card pays up to $100; your copay is $200; you still owe $100.
Fix: Knowing the cap means no nasty surprise — and a self-pay route might actually beat your copay.
3. The pharmacy ran it wrong.
This one is shockingly common. The card has to be applied as a secondary behind your insurance.
Hand the tech this line:
“Can you please run my commercial insurance first, then apply the manufacturer savings card as secondary, using the current BIN, PCN, group, and member ID?”
4. You hit a monthly or yearly limit.
Cards cap both the per-fill savings and the annual total (Zepbound caps around $1,300/year).
Fix: Track your fills so you’re not blindsided late in the year.
5. You’re on Medicare, Medicaid, VA, or TRICARE.
Government plans are excluded from the commercial card.
Fix: Use the Medicare Bridge or your plan benefit instead (next section).
6. The eVoucher and the card got confused.
Some pharmacies auto-apply a digital savings file called an eVoucher; other times the card has to be typed in by hand; and sometimes the card fails and you have to file for a reimbursement afterward.
Fix: If the price is wrong, ask the pharmacy which one they tried, and whether a reimbursement form applies.
Best for: anyone who got a surprise price and wants to fix it before refilling.
Can people on Medicare, Medicaid, VA, or TRICARE use a GLP-1 savings card?
In general, no — manufacturer commercial savings cards are not available to anyone on a government plan like Medicare, Medicaid, VA, or TRICARE. But Medicare changed in a big way for 2026: starting July 1, 2026, eligible Medicare Part D members can get certain GLP-1 weight-loss drugs for $50 a month through a new federal pilot called the Medicare GLP-1 Bridge.
| Bridge detail | What CMS says |
|---|---|
| Dates | Runs – |
| Cost to you | $50/month copay (the drugmakers supply the medicine at a $245/month net price) |
| Drugs included | Foundayo (all forms), Wegovy (injection and tablets, all forms), Zepbound KwikPen only |
| Drugs excluded | Zepbound single-dose pen and single-dose vial are not included |
| How you get it | Your provider submits a prior authorization with your clinical info |
| Who qualifies | Age 18+, enrolled in a Part D or Medicare Advantage drug plan, and meeting BMI/health criteria (BMI ≥35; or ≥30 with certain heart, blood-pressure, or kidney conditions; or ≥27 with prediabetes or certain cardiovascular history) |
Separately, your regular Part D coverage still matters: for 2026, once your out-of-pocket spending on covered drugs hits $2,100, you pay $0 for the rest of the year. And if a GLP-1 is covered under basic Part D for another reason (for example, Zepbound for sleep apnea, or Wegovy for heart-risk reduction), you’d use your Part D benefit for that — not the Bridge.
Medicaid, VA, and TRICARE rules vary by program and state. The commercial card still won’t apply, and a discount coupon won’t always beat your plan benefit — so verify with your plan or pharmacy rather than guessing.
Best for: Medicare, Medicaid, VA, or TRICARE members who need a route that isn’t the $25 card.
Savings card vs. eVoucher vs. GoodRx vs. buying direct — what’s the difference?
These four things get mixed up constantly, and picking the wrong one costs money.
| Option | What it is | Best for | Stacks with insurance? |
|---|---|---|---|
| Manufacturer savings card | Drugmaker copay help | Commercially insured, drug covered | Yes — it rides behind your plan |
| eVoucher | Auto-applied version of the card | Commercially insured | Usually, when the pharmacy supports it |
| GoodRx / SingleCare | Cash discount coupon | Paying cash, no usable coverage | No — it replaces insurance for that fill |
| LillyDirect / NovoCare | Buy direct from the drugmaker | People who know their exact drug | It’s self-pay, not insurance |
What changed for GLP-1 savings cards in 2026?
The 2026 landscape moved fast, and a page written in January is already missing pieces. Three big shifts matter for your wallet.
Foundayo arrived — first weight-loss pill, $149 self-pay floor
Lilly’s orforglipron pill was FDA-approved — the first weight-loss pill with no food or water timing. It came in with a $25 commercial card and a $149 self-pay floor, instantly making it one of the strongest options when coverage is uncertain.
Coverage just widened — as of
CVS Caremark (one of the three largest pharmacy benefit managers) announced it will lift the block on Foundayo starting June 1, 2026 and add Zepbound back as a preferred covered option on October 1, 2026. Wegovy keeps its preferred spot. CVS’s standard formulary reaches tens of millions of people — though employers can still choose not to cover weight-loss drugs. In plain terms: soon, more commercially insured people will be able to make that $25 card work.
Medicare opened the Bridge — $50/mo starting July 1, 2026
The $50/month Medicare GLP-1 Bridge for eligible Part D members starts — the first real low-cost path for a group the $25 card has always left out. Details in the section above.
The lesson across all three: the cards change, the caps change, and coverage changes. A number that was right in 2025 (like Wegovy’s old $225 cap) can be wrong today. That’s why we date-stamp this page and re-check it.
Where to get the prescription so your savings card actually works
A savings card doesn’t write your prescription, check your medical history, or win your prior authorization for you. If you need a clinician and a clear path to coverage, Ro is the strongest first stop for brand-name GLP-1 access and insurance help, while Sesame is the better fit if you’re paying cash and want to compare branded prices and pick your own provider.
| Provider | What they offer | What we verified | Who it fits | Who should skip it |
|---|---|---|---|---|
| Ro (sponsored affiliate link, opens in a new tab) | Brand-name GLP-1 access + insurance help | Free GLP-1 Insurance Coverage Checker (Wegovy, Zepbound, Ozempic) that shows coverage and whether prior authorization is needed; carries Zepbound and Foundayo; pricing starts at $39 the first month, then as low as $74/mo on the annual plan ($149/mo otherwise) | People who need to get approved, or don’t have a prescriber yet | People already covered with a prescriber in hand (just use the free card) |
| Sesame (sponsored affiliate link, opens in a new tab) | Self-pay branded GLP-1 pricing + provider choice | Publishes cash prices for branded GLP-1s and lets you choose a provider; Costco-linked program advertises lower member pricing on some visits | Cash-pay shoppers who want price transparency | People whose plan already covers the drug at a low copay |
Ro — best when you need to get covered. Ro’s free GLP-1 Insurance Coverage Checker shows whether your plan covers a drug and whether prior authorization is required. Its team helps with the insurance paperwork, including that prior authorization — which matters, because the prior authorization is the step that decides whether your $25 card ever activates.
The honest admission, because you deserve one: Ro is not the cheapest route if you already have a prescriber and your plan already covers your drug. In that case, skip the membership and just use the free manufacturer card at your pharmacy. But if your plan denied you, or you don’t have a prescriber yet, that membership pays for itself by getting you approved so the $25 price unlocks.
Best for: people who need to get approved so the savings card works.
Sesame — best when you’re paying cash. If you’re skipping insurance, Sesame lets you compare self-pay prices on branded GLP-1s and choose your own provider.
Best for: people without coverage who want price transparency and provider choice.
Already know your exact drug? You can also go straight to LillyDirect or NovoCare — the drugmakers’ own channels and the source of truth for their prices.
Find your GLP-1 savings path in 60 seconds
The fastest way to know your real price is to answer three questions: what type of insurance you have, whether your plan covers the exact drug, and whether you’re treating weight or diabetes. Use the tables above to match your situation, then use the guide below to know your most likely next step and dollar range.
Commercial insurance + plan covers Wegovy
You’re likely in the $25 lane. Confirm prior authorization and your copay cap before assuming the final number.
Commercial insurance + Foundayo not covered
You’re likely in the self-pay lane, starting at $149/month for the 0.8 mg dose.
Medicare Part D + weight loss
The $25 card won’t apply. Check Medicare GLP-1 Bridge eligibility — $50/month starting July 1, 2026.
Uninsured / cash-pay
No commercial card. Compare manufacturer self-pay, the TrumpRx portal, and a possible free Patient Assistance Program.
Three quick taps, no account needed. After your result, you can check coverage with Ro, compare cash prices on Sesame, or read the Medicare Bridge details.
A quick, important note on what a savings card can’t do
A savings card can lower your cost, but it should never decide which medicine is right for you.
Your diagnosis, your other medications, your history (including any thyroid, pancreas, or gallbladder issues), pregnancy plans, and your clinician’s judgment all matter far more than a coupon. Don’t start, stop, or switch a GLP-1 based on a savings card alone — use this page to understand price and access, then confirm the medicine and dose with a licensed clinician.
Weight-loss brands and diabetes brands aren’t interchangeable. Zepbound, Wegovy, and Foundayo are the weight-loss/obesity options. Ozempic, Mounjaro, and Rybelsus are diabetes options. Some share the same active drug family, but you should compare access paths, not assume you can swap one for another.
Compounded GLP-1s have no manufacturer savings card. Manufacturer cards come from the brand-name makers (Novo Nordisk and Eli Lilly) for their FDA-approved products only. A compounded semaglutide or tirzepatide program is a different category — it may advertise a low flat price, but that’s the pharmacy’s own pricing, not a brand-name manufacturer card, and the two shouldn’t be compared as if they’re the same thing.
Why we built this comparison
If you’ve ever screenshotted a “$25” ad, gotten excited, then watched the pharmacy ring up $157 or $300, you’re not alone — and you didn’t do anything wrong. The most common frustrations we see, again and again, are people whose card “wouldn’t work” at the counter (usually a coverage or processing issue), people blindsided when a cap shrank and their price jumped overnight, and people on Medicare who didn’t realize the commercial card never applied to them in the first place.
That gap — between what the ad promises and what the pharmacy charges — is the whole reason this page exists. Not whether a savings card exists, but whether it actually works for your plan, your pharmacy, and your medicine.
How we verified this
We built this page by checking official drugmaker savings pages, the FDA-approval announcement for Foundayo, CMS’s Medicare GLP-1 Bridge page, and current provider pricing on . We used patient forums only to understand where people get confused — never as proof for any price, safety, or medical claim.
✅ What we actually verified ():
- Foundayo, Zepbound, Wegovy, Ozempic, Mounjaro, Trulicity, and Rybelsus card amounts, caps, and expiration dates (drugmaker pages)
- The commercial-insurance requirement and the Medicare/Medicaid/VA/TRICARE exclusion
- Foundayo’s FDA approval (April 1, 2026) and its $149 self-pay floor
- The Medicare GLP-1 Bridge terms — dates, $50 copay, included drugs, prior-authorization rule, and the fact that the $50 doesn’t count toward your Part D cap (CMS)
- The 2026 Medicare Part D out-of-pocket cap of $2,100 (CMS)
- The CVS Caremark coverage changes (Foundayo June 1, 2026; Zepbound October 1, 2026) — confirmed across major news outlets and CVS Health’s own release
⚠️ What we did NOT verify (and you shouldn’t assume):
- Your specific plan’s drug list — coverage varies by employer and plan
- Every pharmacy’s card-processing workflow
- That any card guarantees approval or a specific final copay
Sources
- Wegovy savings & cost: NovoCare — novocare.com
- Zepbound savings: Eli Lilly — zepbound.lilly.com/savings
- Foundayo savings & coverage: Eli Lilly — foundayo.lilly.com/coverage-savings; FDA approval April 1, 2026
- Ozempic & Rybelsus savings: NovoCare (diabetes savings card)
- Mounjaro & Trulicity savings: Eli Lilly — startlilly.com
- Medicare GLP-1 Bridge: CMS — see our full Medicare GLP-1 Bridge guide
- 2026 Part D out-of-pocket cap: CMS Final CY 2026 Part D Redesign Program Instructions
- CVS Caremark coverage update: CVS Health newsroom, May 28, 2026
- TrumpRx: trumprx.gov
Frequently asked questions about active GLP-1 savings cards in 2026
What is the best GLP-1 with an active savings card in 2026?
For weight loss, the strongest active savings cards belong to Foundayo, Zepbound, and Wegovy — all advertise as little as $25/month with commercial insurance that covers the drug. Foundayo has the lowest verified brand-name self-pay floor at $149/month if your plan doesn’t cover it, which makes it the safest pick when coverage is uncertain.
Can I really get a GLP-1 for $25 a month?
Yes — eligible patients with commercial insurance that covers the drug can pay as little as $25, but it isn’t guaranteed for everyone. You only save up to a monthly cap ($100 for weight-loss brands, $150 for diabetes brands), so if your copay is higher than that cap, you’ll pay the difference.
Can people on Medicare use a GLP-1 savings card?
No — commercial manufacturer savings cards exclude Medicare, Medicaid, VA, and TRICARE. However, eligible Medicare Part D members can get certain GLP-1 weight-loss drugs for $50/month through the Medicare GLP-1 Bridge between July 1, 2026 and December 31, 2027.
Can I use a GLP-1 savings card without insurance?
Usually not — the $25 card needs commercial insurance that covers the drug. If you’re uninsured, look instead at manufacturer self-pay prices (Foundayo from $149, Zepbound vials from $299), the TrumpRx price-comparison portal, or a Patient Assistance Program that may provide the drug free if you qualify by income.
Why didn’t my GLP-1 savings card work at the pharmacy?
The most common reasons are that your plan doesn’t cover the drug, your copay is above the card’s cap, the pharmacy didn’t run the card as secondary behind your insurance, you hit a monthly or yearly limit, or you’re on a government plan. Asking the pharmacy to re-process the card behind your insurance fixes a surprising number of these.
Can I combine GoodRx with a manufacturer savings card?
Usually no. GoodRx and SingleCare are cash-discount coupons, while manufacturer cards work behind your commercial insurance — you generally use one or the other, so have the pharmacy compare which gives you the lower price.
Is Ozempic a good weight-loss savings-card option?
Ozempic is FDA-approved for type 2 diabetes, not weight loss, so it shouldn’t be chosen for weight-loss savings reasons on its own. If your clinician determines a diabetes pathway fits you, its card offers as little as $25/month with commercial coverage.
Do compounded GLP-1s have manufacturer savings cards?
No. Manufacturer savings cards come only from the makers of FDA-approved brand-name drugs. Compounded GLP-1 programs may advertise low flat prices, but those aren’t brand-name manufacturer cards and shouldn’t be compared as if they are.
When do the 2026 GLP-1 savings cards expire?
Eli Lilly’s current terms list a December 31, 2026 expiration for the Foundayo, Zepbound, Mounjaro, and Trulicity cards, and Novo Nordisk’s programs reset annually. Always re-check the official terms before a new fill, because drugmakers can change them at any time.
What should I do if I still don’t know which path fits me?
Use our free 60-second GLP-1 matching quiz — the right next step depends on your insurance type, whether your plan covers the drug, which medicine you’re considering, and whether you need a clinician, prior authorization, or a cash-pay comparison.
Still not sure which GLP-1 program is right for you?
Take our free 60-second matching quiz. You’ll get a practical route based on your insurance, budget, medication preference, and whether you need brand-name coverage, a cash-pay price, or a non-card alternative.
Related guides
- Foundayo vs. Zepbound: full drug comparison
- Zepbound Savings Card 2026: complete guide
- Wegovy pill providers that accept insurance
- Medicare GLP-1 Bridge Program: eligibility and steps
- Ozempic savings card: full details
- Best brand-name GLP-1 via LillyDirect: 8 routes compared
- Best GLP-1 for long-term maintenance